Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Investigated for use/treatment in kidney disease and systemic lupus erythematosus.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.